Newsvine
  • Welcome
  • Help
  • Report Bug
  • Conversation Tracker
  • Your Column
  • Replies
  • Friends
Type Comments Since You Last CheckedArticle Source Last Checked Stop Tracking All Clear Tracking All
Advertise | AdChoices
Log In | Register
Close the Login Panel
Existing users log in below. New users please register for a free account.

New Users:

Existing Users:

E-Mail:
Password:
Forgot Password?
Please enter the e-mail address or domain name you registered with:
E-Mail/Domain:
Back to Login
Log Out
  • Top News
  • Local News
  • World
  • U.S.
  • Sports
  • Politics
  • Tech
  • Entertainment
  • Science
  • Business
  • Health
  • Odd News
  • More
    • Arts
    • Education
    • Environment
    • Fashion
    • History
    • Home & Garden
    • Not News
    • Religion
    • Travel
What is Newsvine?

Updated continuously by citizens like you, Newsvine is an instant reflection of what the world is talking about at any given moment.

Get a Free Account
Help
Fun Stuff
  • Your Clippings
  • Leaderboard
  • E-Mail Alerts
  • Top of the Vine
  • Newsvine Live
  • Newsvine Archives
  • The Greenhouse
  • Recommended Articles
  • Wall of Vineness
Put a Seed Newsvine link on your own site

ALS researcher succumbs to disease he studied

Mon Jan 30, 2012 7:32 PM EST
us-news, health, us, obit, als, researcher, lou-gehrig
Paul Elias, Associated Press
Advertise | AdChoices

SAN FRANCISCO — Dr. Richard Olney, an internationally renowned researcher who dedicated his life to finding a cure for Lou Gehrig's disease, has died after his own eight-year battle with the disease. He was 64.

The University of California, San Francisco announced Monday that Olney died Friday at his Marin County home.

He had spent nearly his entire 25-year research career at UCSF, the last 18 investigating amyotrophic lateral sclerosis, or ALS.

Olney launched the UCSF ALS Center in 1993 to pursue treatments for the disease, which causes patients to gradually lose control of their muscles. It now serves 375 patients.

Olney resigned from the center in 2004 to attend to his own health. He enrolled as the first human subject in a test he helped design of a drug used to combat cancer and the other for AIDS that showed promise in slowing ALS' progress. He adhered to the experiment's rigid guidelines and didn't seek to determine if he was receiving the drugs or medically useless placebos until the end of the test.

"It was typical of Rick to put the value of the medical research before himself and not take the drugs outside the boundaries of the trial," said Dr. Catherine Lomen-Hoerth, an Olney protege who took over leadership of the center. "He knew it was highly unlikely that a treatment would be found during his lifetime, but nothing was going to stop him from doing whatever he could to advance the research."

Olney was in the group that received the actual drugs.

"It may have helped," Lomen-Hoerth said. "It's hard to know. Early-stage clinical trials like this involve low doses that are designed to test drug safety, as opposed to efficacy."

Some 30,000 Americans have ALS, a small number when compared to other brain diseases.

About 10,000 new cases are diagnosed every year. And while about 10 percent of the cases have genetic roots, it's not known how the other 90 percent occur. It's not contagious and much of current research is focused on genetic and environmental factors of disease that still mystifies experts today as much as it did when New York Yankee slugger Lou Gehrig died of it in 1941.

Olney graduated Phi Beta Kappa from the University of Oklahoma with a bachelor's degree in 1968. He received his medical degree from Baylor College of Medicine in Houston in 1973.

He is survived by his wife of 38 years, Paula; two children and a grandson. A private memorial is planned. The family asked for donations to be made Olney's name to the UCSF ALS Center.

© 2012 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
  • Enjoy this article? Help vote it up the 'Vine.

Back To Top | Front Page

Published to:

  • Paul Elias's Column, All of Newsvine
  • Groups: none
  • Regions: San Francisco/Oakland/San Jose
  • Public Discussion (0)
Leave a Comment:
You're in Easy Mode. If you prefer, you can use XHTML Mode instead.
You're in XHTML Mode. If you prefer, you can use Easy Mode instead.
(XHTML tags allowed - a,b,blockquote,br,code,dd,dl,dt,del,em,h2,h3,h4,i,ins,li,ol,p,pre,q,strong,ul)
Newsvine Privacy Statement
As a new user, you may notice a few temporary content restrictions. Click here for more info.
FUN STUFF:
  • Leaderboard |
  • E-Mail Alerts |
  • Top of the Vine |
  • Newsvine Live |
  • Newsvine Archives |
  • The Greenhouse
COMPANY STUFF:
  • Code of Honor |
  • Company Info |
  • Contact Us |
  • Jobs |
  • User Agreement |
  • Privacy Policy |
  • About our ads
LEGAL STUFF:
  • © 2005-2012 Newsvine, Inc. |
  • Newsvine® is a registered trademark of Newsvine, Inc. |
  • Newsvine is a property of msnbc.com